The 2013 text of EU GMP Chapter 1 and 21 CFR 211.192 speak of recording and investigating deviations, and neither gives a number of days. The 30-day limit is the site's own, and inspectors hold a site to its procedure. The alternative is also a site rule: a limit per risk class, with extensions only on a written reason and an interim risk assessment.
The similarity factor f2 compares two dissolution profiles on a scale where 100 is identical and a 10% difference at every time point gives 49.9. FDA and EMA guidance read 50 to 100 as similar, under conditions on units, time points and variability. It is one input to a comparison after a site change.
21 CFR 11.100 sets three general requirements for electronic signatures: each one unique to one individual and never reassigned, identity verified before a signature is assigned, and a certification to FDA that the signatures are the legally binding equivalent of handwritten ones. All three belong in the URS and the site procedure.
Continued process verification is the FDA's Stage 3: assurance during routine production that the process remains in a state of control. EU GMP Annex 15 (2015) calls it ongoing process verification. Continuous process verification, defined in ICH Q8(R2), is an alternative approach to validation. Write the phrase out and cite its source.
A Cpk of 1.33 puts the nearer specification limit 4 standard deviations from the process mean. It is a statistical convention: EU GMP Annex 15 (2015 text) and the FDA guidance of 2011 recommend statistical tools and name no index. With 10 batches the confidence interval is wide, so report the batch count and the interval.
Tabulating twenty or thirty past batches was once called retrospective validation. The 2015 text of EU GMP Annex 15 (section 5) says it is no longer an acceptable approach: a traditional process should undergo prospective validation, with concurrent validation only in exceptional circumstances. The batch history belongs in ongoing process verification.
Five times the batch at the same set-points gives different granules, because some parameters depend on scale. WHO's technology transfer guideline says batch sizes should be compared and the impact assessed where they differ. Compare the equipment, check dust, exhaust and water at the new scale, and settle set-points with trial batches.
An out-of-specification result falls outside the specification or acceptance criteria and starts with a laboratory assessment. An out-of-trend result is inside the limits but breaks the pattern of earlier results. EU GMP Chapter 6 says both should be addressed and investigated, which needs data recorded so that trends can be evaluated.
Two mixers of the same volume are not equivalent if one tumbles and the other uses a ribbon. The FDA's SUPAC guidance speaks of equipment of the same design and operating principles, of the same or a different capacity. WHO's guidelines on technology transfer say the comparison should cover working principle, capacity, make and model.
In today’s pharmaceutical manufacturing environment, operational efficiency is no longer just about maximizing output — it must also align with strict GMP compliance, product quality, and…
How Does an MES Work in Pharmaceutical Manufacturing? A Manufacturing Execution System (MES) acts as the digital backbone of pharmaceutical production, bridging enterprise planning systems and shop floor operations. It ensures that every…
In pharmaceutical manufacturing, maintaining compliance is no longer based only on periodic qualification – it requires continuous environmental oversight.…